Anthony Mato, MD, MSCE

About Me

My primary focus is providing excellent care to people with chronic lymphocytic leukemia (CLL). At MSK, I serve as Director of the CLL Program. I oversee a team of experts who are entirely dedicated to all aspects of diagnosing and treating CLL. Our combined expertise allows us to develop the best treatment plans tailored to each patient’s unique situation. We can safely administer current therapies and also provide access to the newest treatments through clinical trials. Our mission is to provide people with CLL with state-of-the-art monitoring and treatments through clinical research and expertise.

Read more Read less Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • Clinical Expertise: Chronic Lymphocytic Leukemia (CLL); Lymphoproliferative Disorders
  • Languages Spoken: English
  • Education: MD, SUNY Buffalo; MSCE, University of Pennsylvania School of Medicine
  • Residencies: Internal Medicine - Hospital of the University of Pennsylvania
  • Fellowships: Hematology and Oncology - Hospital of the University of Pennsylvania
  • Board Certifications: Internal Medicine; Hematology and Oncology

New Patient Appointments

Making an appointment

Call 646-497-9154

See My Colleagues

Publications

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu J, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977

Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect® CLL registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Hematology. 2016 Dec;175(5):892-903. doi: 10.1111/bjh.14332

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Karbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclaxin Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. Annals of Oncology. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031

Read more Read less Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster S. Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review. Clinical Lymphoma Myeloma and Leukemia. 2017 Dec;17(12):852-56. doi: 10.1016/j.clml.2017.07.007

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology. 2018;19(1):65-75.

Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biology and Therapy. 2018 Jan;19(1):1-2. doi: 10.1080/15384047.2017.1394554

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander D, Hill B, Howlett C, Skarbnik A, Cheson B, Zent C, Pu J, Kiselev P, Goy A, Claxton A, Isaack K, Kennard K, Timlin C, Landsburg D, Winter A, Nasta S, Bachow S, Schuster S, Dorsey C, Svoboda J, Barr P, Ujjani C.Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis. Haematologica (accepted, publication pending).

Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873

Wang J, Morrissette J, Lieberman DB, Timlin C, Schuster SJ, Mato AR. Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations in Chronic Lymphocytic Leukaemia. British Journal of Hematology. 2016 Oct 7. doi: 10.1111/bjh.14315

O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1


Visit PubMed for a full listing of Anthony Mato’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.

Read more Read less Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Insurance

Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more